Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data ...Middle East

MELBOURNE, Australia, Sept. 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) in combination with external beam radiation...

Hence then, the article about final ipax 1 study data confirms safety and tolerability profile for tlx101 preliminary efficacy data was published today ( Wednesday 21/09/2022 - 02:48 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data )

Also on site :

• 13-year-old rider dies following incident at northwest Indiana BMX park
• I'm a Food Editor and These Are the Black-Owned Food & Beverage Brands I Swear By
• 'The Traitors' Star Reveals Rule That Ruins a Public Murder Theory